Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Ellen Matloff and MyGeneCounsel

  • Broadcast in Health
  • 0 comments
Powerful Patient

Powerful Patient

×  

Follow This Show

If you liked this show, you should follow Powerful Patient.
h:47822
s:7509585
archived

Joyce speaks with Ellen Matloff, genetic counselor, about her newest venture, MyGeneCounsel

Ellen Matloff, MS, CGC is the President and CEO of My Gene Counsel. Ellen is the founder and former director of the Cancer Genetic Counseling Program at Yale School of Medicine and a lead plaintiff in the 2013 United States Supreme Court gene patent case. Ellen has authored more than 50 scientific publications in the field, is an established educator, lecturer and media spokesperson and has received national awards for her ongoing patient advocacy efforts.

She was the 2013 honoree of ArtBra New Haven for her work with hereditary breast cancer, and particularly for helping to challenge the validity of patenting the genes for breast cancer.

Ellen’s area of special interest is BRCA I and BRCA II mutations, which vastly increase the probability of a carrier developing breast and/or ovarian cancer. For the past 18 years, she has been dedicated to patient and provider issues in cancer genetic counseling, and the impact of genetic patents on patients and clinical practice.

Ellen was one of the lead plaintiffs in Association of Molecular Pathology v. Myriad Genetics, the landmark case before the U.S. Supreme Court, which challenged the validity of patenting naturally-occurring substances from the human body. Myriad Genetics had patented the BRCA I and II genes, and held the monopoly on testing. This effectively froze research, and made necessary testing unaffordable for many patients, leaving them to make huge decisions about their treatment without vital information. Ellen worked tirelessly for the interests of breast cancer patients and their families. 

Comments

 comments